Earlier reports suggested that KB001-A dose-dependently decreased sputum myeloperoxidase, IL-1 and IL-8, sputum neutrophil elastase, and neutrophil count in CF patients at day 28 of study (McCracken et al., 2016). This evidence concerns the gene CXCL8 and cystic fibrosis.